Cargando…

Targeting of the AKT/m-TOR Pathway: Biomarkers of Resistance to Cancer Therapy——AKT/m-TOR Pathway and Resistance to Cancer Therapy

Resistance to cancer therapy continues to be a major limitation for the successful treatment of cancer. There are many published studies on therapy resistance in breast and prostate cancers; however, there are currently no data on molecular markers associated with resistance. The conflicting data we...

Descripción completa

Detalles Bibliográficos
Autores principales:	SPIRINA, Liudmila V, KONDAKOVA, Irina V, TARASENKO, Natalia V, SLONIMSKAYA, Elena M, USYNIN, Evgeny A, GORBUNOV, Alexey K, YURMAZOV, Zahar A, CHIGEVSKAYA, Svetlana Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	中国肺癌杂志编辑部 2018
Materias:	Mini-Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5972354/ https://www.ncbi.nlm.nih.gov/pubmed/29357975 http://dx.doi.org/10.3779/j.issn.1009-3419.2018.01.09

Ejemplares similares

Effect of Targeted Therapy With Pazopanib on Expression Levels of Transcription, Growth Factors and Components of AKT/m-TOR Signaling Pathway in Patients with Renal Cell Carcinoma
por: Spirina, Liudmila V, et al.
Publicado: (2017)

Progesterone Receptor Expression in the Benign Prostatic Hyperplasia and Prostate Cancer Tissues, Relation with Transcription, Growth Factors, Hormone Reception and Components of the AKT/mTOR Signaling Pathway
por: Spirina, Liudmila V, et al.
Publicado: (2020)

Regulation of Immunity in Clear Cell Renal Carcinoma: Role of PD-1, PD-L1, and PD-L2
por: Spirina, Liudmila, et al.
Publicado: (2021)

Molecular Protein and Expression Profile in the Primary Tumors of Clear Cell Renal Carcinoma and Metastases
por: Spirina, Liudmila V., et al.
Publicado: (2020)

Targeting the PI3K/Akt/mTOR pathway in non‐small cell lung cancer (NSCLC)
por: Tan, Aaron C.
Publicado: (2020)

Molecularly targeting the PI3K-Akt-mTOR pathway can sensitize cancer cells to radiotherapy and chemotherapy
por: Wang, Ziwen, et al.
Publicado: (2014)

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
por: Li, Xiaoman, et al.
Publicado: (2016)

PI3K/AKT/mTOR Pathway in Angiogenesis
por: Karar, Jayashree, et al.
Publicado: (2011)

Regulation of Osteoclast Growth and Fusion by mTOR/raptor and mTOR/rictor/Akt
por: Tiedemann, Kerstin, et al.
Publicado: (2017)

Autophagy activation promotes bevacizumab resistance in glioblastoma by suppressing Akt/mTOR signaling pathway
por: Huang, He, et al.
Publicado: (2018)

Esomeprazole Alleviates Cisplatin Resistance by Inhibiting the AKT/mTOR Pathway in Ovarian Cancer Cells
por: Duan, Jingya, et al.
Publicado: (2023)

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
por: Glaviano, Antonino, et al.
Publicado: (2023)

Inhibition of the AKT/mTOR pathway negatively regulates PTEN expression via miRNAs: Effect of Akt/mTOR inhibition on PTEN expression
por: Wan, Linyan, et al.
Publicado: (2022)

The Paradox of Akt-mTOR Interactions
por: Vadlakonda, Lakshmipathi, et al.
Publicado: (2013)

Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
por: Atefi, Mohammad, et al.
Publicado: (2011)

FGFR1 Induces Acquired Resistance Against Gefitinib By Activating AKT/mTOR Pathway In NSCLC
por: Zhang, Dan, et al.
Publicado: (2019)

Excitotoxic glutamate causes neuronal insulin resistance by inhibiting insulin receptor/Akt/mTOR pathway
por: Pomytkin, Igor, et al.
Publicado: (2019)

Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer
por: Dong, Chao, et al.
Publicado: (2021)

Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic
por: Skolariki, Aglaia, et al.
Publicado: (2022)

The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis
por: Platé, Manuela, et al.
Publicado: (2020)

PD-L1 Status in Gastric Cancers, Association with the Transcriptional, Growth Factors, AKT/mTOR Components Change, and Autophagy Initiation
por: Spirina, Liudmila, et al.
Publicado: (2021)

Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
por: Li, Qingfang, et al.
Publicado: (2022)

The Clinical and Prognostic Significance of Activated AKT-mTOR Pathway in Human Astrocytomas
por: El Habr, Elias A., et al.
Publicado: (2012)

Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs
por: Markman, Ben, et al.
Publicado: (2010)

Essential Roles of mTOR/Akt Pathway in Aurora-A Cell Transformation
por: Taga, Makoto, et al.
Publicado: (2009)

AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV
por: Bhatt, Aadra P., et al.
Publicado: (2013)

Activation of Akt/mTOR Pathway Is Associated with Poor Prognosis of Nasopharyngeal Carcinoma
por: Wang, Weiyuan, et al.
Publicado: (2014)

Akt1 Enhances CA916798 Expression through mTOR Pathway
por: Wang, Yu-Liang, et al.
Publicado: (2013)

SIL1 functions as an oncogene in glioma by AKT/mTOR signaling pathway
por: Xu, Hao, et al.
Publicado: (2018)

PI3K/AKT/mTOR pathway in pulmonary carcinoid tumours
por: Zhang, Zixuan, et al.
Publicado: (2017)

Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
por: Sun, Eun Jin, et al.
Publicado: (2021)

PI3K/AKT/mTOR pathway in tumor progression of oligodendrogliomas
por: Lisi, Lucia
Publicado: (2020)

Dapagliflozin Improves Diabetic Cardiomyopathy by Modulating the Akt/mTOR Signaling Pathway
por: Ren, Mengxiang, et al.
Publicado: (2022)

mTOR signalling pathway - A root cause for idiopathic autism?
por: Ganesan, Harsha, et al.
Publicado: (2019)

Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer
por: Pungsrinont, Thanakorn, et al.
Publicado: (2021)

Involvement of Akt-1 and mTOR in Sensitivity of Breast Cancer to Targeted Therapy
por: Sokolosky, Melissa L., et al.
Publicado: (2011)

PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer
por: Zhu, Kunrui, et al.
Publicado: (2022)

PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance
por: Edlind, Merritt P, et al.
Publicado: (2014)

Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer
por: Mishall, Katie M., et al.
Publicado: (2017)

PI3K/AKT/mTOR pathway promotes progestin resistance in endometrial cancer cells by inhibition of autophagy
por: Liu, Hua, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_evfv05vofdagssc88sc2cn7t5t